Posted by Michael Wonder on 16 Jul 2021
HutchMed’s marketing authorisation application for surufatinib submitted and validated by the European Medicines Agency
15 July 2021 - EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumours.
Hutchmed today announces that the EMA has validated and accepted its marketing authorisation application for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumours.
